Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Ceftazidime after bone marrow graft. Current aspects].

D Blaise1, D Maraninchi, A M Stoppa

  • 1Unité de Transplantation médullaire, Institut Paoli-Calmettes, Marseille.

Presse Medicale (Paris, France : 1983)
|October 26, 1988
PubMed
Summary

Bone marrow transplant recipients face deep aplasia and immune suppression, leading to frequent infections. Researchers are investigating ceftazidime as a potentially kidney-sparing antibiotic option for these vulnerable patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT.

Bone marrow transplantation·2026
Same author

Foliar efficacy of phosphorous formulations for rainfed cotton with graded levels.

Scientific reports·2026
Same author

Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL-a report from the EBMT registry.

Bone marrow transplantation·2024
Same author

Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study.

Bone marrow transplantation·2023
Same author

Related versus unrelated allogeneic HPC graft cryopreservation: a single-center experience in the context of the global COVID-19 pandemic.

Bone marrow transplantation·2021
Same author

Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT.

Bone marrow transplantation·2020

Area of Science:

  • Hematology
  • Infectious Diseases
  • Pharmacology

Context:

  • Bone marrow transplantation (BMT) results in profound aplasia, compromising immune defenses and barrier integrity.
  • Patients undergoing BMT are at high risk (30-40%) for life-threatening septicaemia, often caused by Gram-positive bacteria.
  • Current empirical broad-spectrum antibiotic use effectively reduces immediate infection mortality but raises concerns due to nephrotoxic co-administered drugs like cyclosporin A and amphotericin B.

Purpose:

  • To identify antibiotics with minimal nephrotoxic effects for use in bone marrow transplant recipients.
  • To evaluate the safety and efficacy of ceftazidime in managing infections post-BMT, considering its renal impact.

Summary:

  • Aplasia post-BMT severely impairs natural defenses, increasing susceptibility to infections, particularly Gram-positive septicaemia.
  • Empirical broad-spectrum antibiotic therapy is crucial for reducing early mortality but necessitates careful consideration of nephrotoxicity.
  • Ceftazidime is under investigation, alone or in combination, for its potential as a kidney-sparing antibiotic in this patient population.

Impact:

  • Optimizing antibiotic selection in BMT can improve patient outcomes by reducing infection-related mortality and minimizing drug-induced kidney damage.
  • Findings from ceftazidime trials may guide clinical practice, offering safer therapeutic options for immunocompromised patients.
  • Advancing antibiotic strategies in BMT is critical for enhancing the long-term success and quality of life for transplant survivors.

Related Experiment Videos